MALAT1 and glioma: Up-regulation of the lncRNA MALAT1 has been reported to correlate with tumor progression and poor prognosis in RCC (Zhang et al., 2015), while some lncRNAs have been reported in other tumors, such as HOXA11-AS, which was regarded as a biomarker of poor progression in glioma (Wang et al., 2016a; Wang et al., 2016b).